olaparib


( Last Updated : March 15, 2023)
Generic Name:
olaparib
Project Status:
Pending
Therapeutic Area:
Metastatic castration-resistant prostate cancer (mCRPC)
Manufacturer:
AstraZeneca Canada Inc.
Call for patient/clinician input open:
Brand Name:
Lynparza
Project Line:
Reimbursement Review
Project Number:
PC0319-000
Call for patient/clinician input closed:
Tumour Type:
Genitourinary

Details


Manufacturer Requested Reimbursement Criteria1:
‚ÄčOlaparib in combination with abiraterone and prednisone or prednisolone is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) for whom chemotherapy is not clinically indicated.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
‚ÄčOlaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC).
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.